Revance Therapeutics (RVNC) Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RVNC shares.
View RVNC analyst ratings or view top-rated stocks.

7 Wall Street analysts have issued 12 month price objectives for Revance Therapeutics' stock. Their RVNC share price forecasts range from $20.00 to $44.00. On average, they expect the company's stock price to reach $33.90 in the next twelve months. This suggests a possible upside of 185.1% from the stock's current price.
View analysts price targets for RVNC or view top-rated stocks among Wall Street analysts.

Revance Therapeutics' stock was trading at $18.46 at the beginning of 2023. Since then, RVNC stock has decreased by 35.6% and is now trading at $11.89.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our RVNC earnings forecast.

Revance Therapeutics, Inc. (NASDAQ:RVNC) announced its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by $0.08. The biopharmaceutical company had revenue of $58.13 million for the quarter, compared to analyst estimates of $58.71 million. Revance Therapeutics had a negative trailing twelve-month return on equity of 903.28% and a negative net margin of 191.93%. Revance Therapeutics's quarterly revenue was up 104.9% on a year-over-year basis. During the same period last year, the firm posted ($0.88) EPS.

ETFs with the largest weight of Revance Therapeutics (NASDAQ:RVNC) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO).

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

Revance Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Capital World Investors (10.89%), JPMorgan Chase & Co. (5.34%), Thrivent Financial for Lutherans (3.69%), Alliancebernstein L.P. (2.95%), State Street Corp (2.33%) and Jennison Associates LLC (2.19%). Insiders that own company stock include Angus C Russell, Aubrey Rankin, Carey Oconnor Kolaja, Dustin S Sjuts, Dwight Moxie, Mark J Foley and Tobin Schilke.
View institutional ownership trends.

Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RVNC stock can currently be purchased for approximately $11.89.

Revance Therapeutics (NASDAQ:RVNC) has a market capitalization of $1.05 billion and generates $132.57 million in revenue each year. The biopharmaceutical company earns $-356,420,000.00 in net income (profit) each year or ($4.53) on an earnings per share basis.

The company employs 534 workers across the globe.

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The official website for the company is www.revance.com. The biopharmaceutical company can be reached via phone at (615) 724-7755, via email at jherbert@revance.com, or via fax at 510-742-3401.